629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory

A first in human Phase 1 trial of LY4152199 a B cell activation factor receptor BAFF R T cell engager bispecific antibody in patients with previously treated B cell malignancies BAF FRontier 1 Trial in Progress

Odronextamab treatment for patients with rare subtypes of relapsed refractory R R aggressive B cell non Hodgkin lymphoma B NHL Updated efficacy and safety analyses from a dedicated cohort of the ELM 2 study

Risk factors for failure to complete step up dosing of bispecific antibody therapy for B cell lymphomas

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed Refractory transformed indolent lymphoma

Real world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system CNS lymphoma

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin GemOx versus rituximab plus GemOx R GemOx in patients with relapsed refractory R R diffuse large B cell lymphoma DLBCL 3 year follow up of STARGLO

Prognostic role of FDG PET in outcomes of relapsed refractory large B cell lymphoma treated with CD3 CD20 directed bispecific antibodies

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide doxorubicin and prednisone plus rituximab in diffuse large B cell lymphoma Updated analysis of waveline 007

CD19 expression is preserved following CD19 directed monoclonal antibody therapy with tafasitamab

Sustained remissions beyond 4 years with epcoritamab monotherapy Long term follow up results from the pivotal EPCORE NHL 1 trial in patients with relapsed or refractory large B cell lymphoma

Durable responses in patients with large B cell lymphoma and 3 prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed refractory R R large B cell lymphoma LBCL in the second line 2L and third line and later 3L settings A subgroup analysis

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed refractory large B cell lymphoma